Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Pontine Glioma (DIPG) Drug Development Pipeline Study, H1 2018 - ResearchAndMarkets.com

Research and Markets
Posted on: 28 Feb 18

The "Pontine Glioma (DIPG): Drug Development Pipeline Study, H1 2018" report has been added to ResearchAndMarkets.com's offering.

The most comprehensive pipeline review Diffuse Intrinsic Pontine Glioma (DIPG) - Drug Development Pipeline Study provides in-depth analysis and update information on Diffuse Intrinsic Pontine Glioma (DIPG) pipeline drugs. Current status of all the drugs in the Diffuse Intrinsic Pontine Glioma (DIPG) pipeline is provided in the research work.

The report provides detailed analysis of Diffuse Intrinsic Pontine Glioma (DIPG) pipeline including companies involved, drugs in different stages of development, drug development details across regions (North America, Europe, Asia Pacific and Rest of the World). Further, the Diffuse Intrinsic Pontine Glioma (DIPG) report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Diffuse Intrinsic Pontine Glioma (DIPG) industry.

Excerpts from Diffuse Intrinsic Pontine Glioma (DIPG)- Drug Development Pipeline Study:

Pontine Glioma pipeline comprises of 24 drugs under development as of February 2018. Of these, 6 drugs are in Phase 1 and 3 drugs are in phase 1/2. Further, 8 drugs are in Phase 2 while 1 drug is in Phase 2/3 stage. In addition, 6 drugs are in Pre-Clinical Stage.

Eight drugs have been granted with Orphan drug designation by FDA/ EMA.

37 companies are developing the pipeline for Pontine Glioma. Of this, all the companies are developing one drug each and the Abbvie/ Seattle Genetics, Inc therapeutic candidate- ABT-414 is in Phase 2/3.

DIPG is an aggressive type of malignant glioma, arising from glioma tissue. It occurs around pons (brain stem) and impacts the cranial nerves. It also affects the long-tracks in the brain.

Symptoms include double-vision, unable to close eyelids, dropping a side of the face, difficulties in chewing, speech and walking. The solid tumor type is aggressive and accordingly, symptoms also rapidly develop.

As these are observed in the bottom area of the brain, they are tough to be treated. Currently, there is no cure for pontine glioma and any FDA / EMA approved treatment exists.

Products Mentioned:

  • 8H9 I-124 mAb
  • Ad-RTS-hIL-12
  • Afatinib
  • Antineoplastons A10/AS2-1
  • APX 005M
  • AZD1775
  • azurin p28
  • Cannabidiol
  • Crenolanib
  • Depatuxizumab mafodotin
  • DSP-7888
  • Jevtana(Cabazitaxel)
  • LOXO-101
  • MDNA55
  • MTX110
  • Nivolumab
  • ONC201
  • ORX-101
  • panobinostat
  • Pidilizumab
  • Pomalidomide
  • Tasadenoturev(DNX 2401)
  • Trilexium (TRXE-009-1)
  • WP1066

Summary:

Pontine Glioma pipeline comprises of 24 drugs under development as of February 2018. Of these, 6 drugs are in Phase 1 and 3 drugs are in phase 1/2. Further, 8 drugs are in Phase 2 while 1 drug is in Phase 2/3 stage. In addition, 6 drugs are in Pre-Clinical Stage.

Eight drugs have been granted with Orphan drug designation by FDA/ EMA.

37 companies are developing the pipeline for Pontine Glioma. Of this, all the companies are developing one drug each and the Abbvie/ Seattle Genetics, Inc therapeutic candidate - ABT-414 is in Phase 2/3.

Key Topics Covered:

1 List of Figures & Tables

2 Executive Summary

3 Pontine Glioma- Company Wise Pipeline Analysis

4 Pontine Glioma Pipeline Drug Snapshots

5 Recent Developments in Pontine Glioma Pipeline

6 Appendix

Companies Mentioned

  • AbbVie Inc
  • Alcyone Lifesciences Inc.
  • Apexigen Inc.
  • Arog Pharmaceuticals Inc
  • Array BioPharma
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb International Corporation
  • Burzynski Research Institute
  • CDG Therapeutics Inc.
  • Celgene Corporation
  • DNAtrix Inc.
  • Hadassah Medical Organization
  • Insys Therapeutics Inc
  • Kazia Therapeutics Ltd
  • Loxo Oncology Inc
  • Medicenna Therapeutics
  • Midatech Pharma Plc
  • Moleculin Biotech Inc
  • National Cancer Institute
  • Novartis AG
  • Oncoceutics Inc.
  • OncoRx Pharmaceuticals
  • Pediatric Brain Tumor Consortium
  • Pfizer Inc
  • Sanofi SA
  • Seattle Genetics Inc./ Science Pharmaceuticals
  • Senzer Pharmaceuticals
  • Sophiris Bio
  • St. Jude Children's Research Hospital
  • Sumitomo Dainippon Pharma Co Ltd
  • Weill Medical College of Cornell University
  • Y-mAbs Therapeutics
  • ZIOPHARM Oncology Inc.

For more information about this report visit https://www.researchandmarkets.com/research/lhfbzv/pontine_glioma?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180228005678/en/

Business Wire
www.businesswire.com

Last updated on: 28/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.